Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs

Andrea Wittig,1 Heinrich F. Arlinghaus,3 Christian Kriegerkotte,3 Raymond L. Moss,4 Klaas Appelman,5 Kurt W. Schmid,2 and Wolfgang A.G. Sauerwein1

1Department of Radiation Oncology and 2Institute for Pathology and Neuropathology, University Duisburg-Essen, University Hospital Essen, Essen, Germany; 3Physikalisches Institut, Westfälische Wilhelms-Universität Münster, Münster, Germany; 4HFR Unit, Institute for Energy, Joint Research Centre, European Commission; and 5Nuclear Research and Consultancy Group, NRG, Petten, The Netherlands

Abstract

The exact intracellular localization and distribution of molecules and elements becomes increasingly important for the development of targeted therapies and contrast agents. We show that laser postionization secondary neutral mass spectrometry (laser-SNMS) is well suited to localize particular elements and small molecules with subcellular spatial resolution applying the technique exemplarily to Boron Neutron Capture Therapy (BNCT). We showed in a murine sarcoma that the drugs used for clinical BNCT, namely L-para-boronophenylalanine (700 mg/kg body weight i.p.) and sodium mercaptoundecahydro-closo-dodecaborate (200 mg/kg body weight i.p.), transport the therapeutic agent 10B into the cytoplasm and into the nucleus itself, the most sensitive area of the cell. Sodium mercaptoundecahydro-closo-dodecaborate distributes 10B homogeneously and L-para-boronophenylaniline heterogeneously. When combining laser-SNMS with prompt γ-ray analysis as a screening technique, strategies for BNCT can be elaborated to develop new drugs or to improve the use of existing drugs on scientifically based evidence. The study shows the power of laser-SNMS in the early stages of drug development, also outside BNCT. [Mol Cancer Ther 2008;7(7):1763 – 71]

Introduction

Imaging of elements and molecules with subcellular spatial resolution becomes increasingly important in the development of modern therapeutic and diagnostic strategies in medicine. Such strategies rely on the capability of specialized compounds to selectively target specific cells. The application of imaging techniques, such as mass spectrometry, provides an excellent tool to guide decisions already in the initial stages of drug development. Laser postionization secondary neutral mass spectrometry (laser-SNMS) can simultaneously detect atoms, their isotopes and molecules (through well defined small fragments), in tissue with high sensitivity and with microscopic spatial resolution (1). The principal advantage of this technology is the ability to directly observe the distribution of elements and molecules without specific labeling by fluorescent or radioactive probes. Laser-SNMS seems to particularly provide benefit for drug testing in Boron Neutron Capture Therapy (BNCT). BNCT is a biologically targeted form of radiotherapy, which uses the ability of the isotope 10B to capture thermal neutrons leading to the nuclear reaction 10B(α,γ)Li. This reaction produces 478 keV γ-rays, 4He and 7Li particles. The latter two have high linear energy transfer properties and therefore a high biological effectiveness relative to conventional photon irradiation. The range of these particles in tissue is limited to ~10 μm, which confines their effect to one cell diameter, thus providing the potential for a targeted irradiation of tumor cells.

10B-containing compounds used for BNCT do not have any therapeutic effect by themselves. As a consequence, conventional methods to test the efficacy of candidate drugs are not applicable. However, data on the macroscopic 10B concentration and the microscopic 10B distribution in tumors and surrounding healthy tissues are prerequisites to identify 10B compounds, which selectively target specific tumor types. Quantitative approaches, such as prompt γ-ray analysis (PGRA), can reliably yield average 10B concentrations to within 1 ppm from gross tissue specimens (2). Sample volumes, however, that can be measured with these methods are much larger than the volume irradiated by the 10B(α,γ)Li reaction. In BNCT, the clinical efficacy of the therapy is substantially increased if the 10B atoms are positioned close to a sensitive structure (the cell nucleus). Therefore, the ability to image the 10B distribution in individual cells helps both in judging the potential of a certain drug in a given specific tumor type and in the understanding of underlying mechanisms of selectivity.

This study evaluates the potential of laser-SNMS in assessing the microscopic 10B distribution in tissue samples.
The subcellular distribution of $^{10}$B, using the two experimental compounds available for clinical BNCT, namely $\nu$-para-boronophenylalanine (BPA; ref. 3) and sodium mercaptoundecahydro-closo-dodecaborate (BSH; ref. 4), was compared. The second objective was to combine the information gained from laser-SNMS and PGRA using the same samples to evaluate if the two compounds BSH and BPA selectively accumulate in soft-tissue sarcoma offering a treatment option for this tumor type. The macroscopic $^{10}$B concentration in a murine tumor model was compared with the $^{10}$B concentration in the clinically relevant normal tissues, which might be dose limiting.

Materials and Methods

Animals and Tumors

Six- to 9-week-old male nude mice (HsdCb:NMRI-nu/nu, kept at the Central Animal Facility of the University Hospital, Duisburg-Essen) were used for experiments. The health status of the mice was investigated quarterly in accordance with the recommendations of the Federation of European Laboratory Animal Science Associations (5). Animals had unlimited access to water and a high caloric nude mouse diet (12 ZH 10, Altromin). The experiments were authorized by the regulatory authority under TSG 683-02.

The histologic investigation of the MuEs tumor showed a tumor composed almost exclusively of spindle cells, which showed an infiltrative growth to adjacent nonneoplastic tissues. The tumors developed variably amounts of necrotic areas. Abundant mitoses were present. The vasculature within the tumors was thin-walled and usually dilated. The PAS reaction and AB-PAS reaction were negative as well as the immunohistochemical staining reactions for p53, epoxide Ki-67 (MB-1), and epithelial cytokeratin (LU-5). The tumor doubling time was 3 days. Tumor chunks of 2 to 3 mm were transplanted s.c. in the chest wall of anaesthetized mice. $^{10}$B uptake studies were done on tumors with a diameter of 10 to 15 mm.

Boron Compounds

BSH (Na$_2^{10}$B$_{12}$H$_{11}$SH) was designed by Soloway et al. (4) to treat brain tumors. It was investigated clinically in malignant glioma (6, 7) and glioblastoma multiforme (European Organisation for Research and Treatment of Cancer 11961; refs. 8, 9). BPA (CaH$_2^{10}$BNO$_4$) is a derivative of the neutral amino acid phenylalanine (3). It was used in clinical trials to treat glioblastoma and melanoma (10–12) and in combination with BSH to treat squamous cell carcinoma of head and neck (13, 14).

The systematic quality control of BSH and BPA (Katchem) and the preparation of injection solutions were done according to standard operating procedures established for the clinical BNCT trials of the European Organisation for Research and Treatment of Cancer (trials 11961, 11001, and 11011; refs. 8, 15, 16).

In keeping with the time range reported to be optimal in murine models (17–19), samples were collected 1.5 h after i.p. BPA injection (700 mg/kg) and 2.5 h after i.p. BSH injection (200 mg/kg). These doses correspond to twice the dose, which is used in the treatment protocols of the European Organisation for Research and Treatment of Cancer. One group of animals received either BSH or BPA; a third group received both drugs sequentially. Control animals were injected with saline following the same schedule.

Sample Preparation and Analysis with PGRA

Samples were taken with the animals deeply anaesthetized. Blood samples were taken by intracardial cannulation. Then, tumors, samples of skin, muscle, bone, and fat were removed. The samples were immediately weighed and stored in airtight containers at −20°C. The $^{10}$B concentration in tissue or blood was analyzed by PGRA at the High Flux Reactor HFR Petten. PGRA measures the integral $^{10}$B concentration in the sample volume by quantification of the 478 keV photon emission during the $^{10}$B(n,γ)$^7$Li reaction (2). Measurements were cross-calibrated with inductively coupled plasma-emission spectroscopy. The minimum number of animals per data point was 4. The Kruskal-Wallis test was used to test for the global differences between treatments and the Wilcoxon test to compare each treatment group using SAS Software. $P$ values < 0.05 were considered to prove statistical significance.

Sample Preparation and Analysis with Laser-SNMS

The feasibility of laser-SNMS in tissues depends on special cryopreparation techniques to preserve the chemical and structural integrity of living cells. Moreover, samples must withstand ion beam bombardment and high vacuum in the analysis chamber. Besides minimizing the time between tissue excision and sample freezing, it is important to maximize the cooling rate during the freezing process. A dedicated cryogenic sample preparation technique with a high cooling rate was validated for tissue samples (20, 21). Liquid propane was cooled below its boiling temperature using liquid nitrogen, thus accelerating the cooling process and preventing evaporation of propane at the contact surface of the immersed specimen. This allowed cooling rates of up to $10^7$ K/s on the surface of the sample. Samples were prepared on conducting support material to prevent charging of the sample during ion bombardment (22). Small pieces of tissue (<1 mm$^3$) were placed on gold specimen carriers (Baltec) and shot into the liquid propane at high velocity. A slice of tissue was sectioned from each block (Leika UCT ultramicrotome) at 193 K to remove damaged cells and contamination resulting from sample manipulation. The remaining block was freeze dried at a temperature of 193 K and a pressure of <1 Pa and stored under dry atmosphere. The face of the freeze-dried block was analyzed.

A combined gridless reflectron-based cryolaser-SNMS/TOF-secondary ion mass spectrometry (SIMS) instrument was used for the mass spectrometry analysis. Samples were bombarded with a pulsed 30 keV Ga$^+$ liquid metal ion gun (dc current: 1.4 nA) with a beam diameter of ~200 mm (total ion dose density: $1 \times 10^{13}–1 \times 10^{15}$ cm$^{-2}$). A focused excimer laser beam ($\lambda = 193$ nm, repetition rate: 200 Hz, pulse width: 10 ns, pulse energy: 100 mJ, and spot size...
Table 1. Variation in mean ± SD absolute $^{10}$B concentration and mean ± SD $^{10}$B concentration ratio between tumor/blood and tumor/healthy tissues following an injection of BPA (700 mg/kg, 1.5 h before tissue sampling) or BSH (200 mg/kg, 2.5 h before tissue sampling) or both compounds sequentially

<table>
<thead>
<tr>
<th>Absolute $^{10}$B concentration (ppm)</th>
<th>BSH</th>
<th>BPA</th>
<th>BSH + BPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor</td>
<td>14.9 ± 4.7</td>
<td>31.3 ± 4.0</td>
<td>36.6 ± 11.1</td>
</tr>
<tr>
<td>Blood</td>
<td>20.6 ± 8.0</td>
<td>13.9 ± 2.5</td>
<td>31.1 ± 11.1</td>
</tr>
<tr>
<td>Skin</td>
<td>8.4 ± 2.5</td>
<td>14.6 ± 3.2</td>
<td>20.11 ± 8.2</td>
</tr>
<tr>
<td>Muscle</td>
<td>2.2 ± 1.3</td>
<td>12.9 ± 1.8</td>
<td>13.2 ± 4.0</td>
</tr>
<tr>
<td>Bone</td>
<td>6.5 ± 1.3</td>
<td>7.5 ± 1.1</td>
<td>16.7 ± 1.1</td>
</tr>
<tr>
<td>Fat</td>
<td>1.5 ± 1.2</td>
<td>3.8 ± 1.3</td>
<td>3.6 ± 2.0</td>
</tr>
</tbody>
</table>

$^{10}$B concentration ratio

<table>
<thead>
<tr>
<th>Tumor/blood</th>
<th>BSH</th>
<th>BPA</th>
<th>BSH + BPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.7 ± 0.1</td>
<td>2.3 ± 0.5</td>
<td>1.3 ± 0.5</td>
<td></td>
</tr>
<tr>
<td>1.7 ± 0.4</td>
<td>2.3 ± 0.3</td>
<td>1.8 ± 0.4</td>
<td></td>
</tr>
<tr>
<td>8.3 ± 3.2</td>
<td>2.5 ± 0.4</td>
<td>2.9 ± 0.6</td>
<td></td>
</tr>
<tr>
<td>2.6 ± 0.4</td>
<td>4.4 ± 1.1</td>
<td>1.9 ± 0.8</td>
<td></td>
</tr>
<tr>
<td>12.1 ± 4.1</td>
<td>8.8 ± 3.2</td>
<td>11.8 ± 5.4</td>
<td></td>
</tr>
</tbody>
</table>

The lowest mean $^{10}$B concentration in the sarcoma was observed after BSH injection (Table 1). After BPA injection, the $^{10}$B concentration was intermediate. The subsequent injection of BSH and BPA led to the highest $^{10}$B concentration in the sarcoma. The increase was little below additive (Table 1). The amount of $^{10}$B delivered by 200 mg BSH/kg body weight is higher (113.18 mg $^{10}$B/kg) compared with 700 mg BPA/kg body weight (33.36 mg $^{10}$B/kg), which has to be considered when the absolute $^{10}$B concentrations are compared. The $^{10}$B concentration ratio between tumor/blood after BSH injection was significantly lower compared with a BPA injection ($P < 0.01$). The $^{10}$B concentration ratio between tumor/blood after a sequential injection of BSH and BPA was significantly lower compared with a single BPA injection ($P < 0.01$) but significantly higher than after BSH injection ($P < 0.01$) (Fig. 1).

The $^{10}$B concentration ratios of tumor/healthy tissues are depicted in Fig. 2. The $^{10}$B concentration ratio tumor/skin was not significantly different after BSH, BPA, or an injection of both compounds. The highest $^{10}$B concentration ratios were found between tumor and fat; however, the ratios were not statistically different after an injection of BSH, BPA or both compounds. In contrast to these results, the $^{10}$B ratio tumor/muscle was more favorable for the drug BSH as the $^{10}$B concentration ratio was significantly higher after BSH compared with the injection of BPA or both compounds ($P < 0.01$). The ratio was not statistically different after injection of BPA or BPA + BSH ($P = 0.088$). The $^{10}$B concentration ratio tumor/bone was significantly higher after BPA injection compared with BSH injection ($P < 0.01$) and injection of BSH + BPA ($P < 0.01$). The ratio did not significantly differ after BSH injection compared with BSH + BPA ($P = 0.11$).

Analysis of Boron Distribution with Laser-SNMS

In Figs. 3–5, the localization of specific ions and small molecules in tumor samples is shown. The $^{10}$B distribution, as analyzed with laser-SNMS, was colocalized with specific cellular structures. These structures were identified by imaging the distribution of index molecules, which represent particular cell contents. For example, phosphorous is a constituent of polar head groups of phospholipids in lipids, proteins, and DNA. As such, the phosphorous signal is higher inside cells and thus can be used to identify

Results

$^{10}$B Concentrations in Tumors Measured with PGRA

In Figs. 3–5, the localization of specific ions and small molecules in tumor samples is shown. The $^{10}$B distribution, as analyzed with laser-SNMS, was colocalized with specific cellular structures. These structures were identified by imaging the distribution of index molecules, which represent particular cell contents. For example, phosphorous is a constituent of polar head groups of phospholipids in lipids, proteins, and DNA. As such, the phosphorous signal is higher inside cells and thus can be used to identify
cells and cell boundaries. Earlier studies on membrane model systems have shown that C3H8Ni is a typical fragment of the quaternary amino group in the cholbin head groups of lipids like phosphocholin and sphingomyelin (24, 25). This molecule was therefore used to identify membrane systems—not only the plasma membrane but also membrane layers surrounding cell organelles. CN is a small fragment, which is a constituent of many molecules, especially proteins and nucleic acids. It is thus found over the entire cellular area (26). Furthermore, the bases purine and pyrimidine in the DNA contain many CN bindings. A high contrast was observed in the pattern of CN with spots of much higher intensity with a diameter of \(5 \text{ to } 7 \text{ \(\mu\text{m}\)} in some intracellular areas (Figs. 3–5). In these areas, the C3H8N signal was low. It is likely that the nucleic membrane was removed in these areas by the fracturing process, leaving behind an open nucleus.

The \(^{10}\text{B}\) image of the tumor treated with BSH (Fig. 3) shows a quite homogeneous distribution of the \(^{10}\text{B}\) signal over the entire sample. Specific colors for each type of ion (red for CN, green for C3H8N, and blue for \(^{10}\text{B}\)) were used for the superimposition of various ion images. This colocalization shows that the \(^{10}\text{B}\) signal is clearly present in areas where also an intense C3H8N signal is present but also in areas with an intense CN signal. Within an individual laser-SNMS image, the level of brightness is directly proportional to the signal intensity. The \(^{10}\text{B}\) signal is almost equally high in extracellular areas and within the cells in the cytoplasm and shows a quite homogeneous distribution.

In Fig. 4, ion images are shown from the MuEs sarcoma treated with BPA. Clearly, in this sample, the \(^{10}\text{B}\) signal is not homogeneously distributed but shows distinct differences between cells and inside single cells. \(^{10}\text{B}\) signals are present within the cytoplasm and within the cell nucleus. However, there are no regions within the cells in which the \(^{10}\text{B}\) signal is especially high and therefore suggesting one particular binding site.

A similar picture was observed in tumor samples of mice injected with both BSH and BPA (Fig. 5). The \(^{10}\text{B}\) signal was not homogeneously distributed and had varying intensities within single cells and within the tissue. Clearly, \(^{10}\text{B}\) signals were again colocalized with areas of high intensity of the CN signal and the C3H8N signal. Obviously, it was not possible to distinguish whether a specific \(^{10}\text{B}\) atom was delivered by BSH or BPA. This might be investigated by using, for example, \(^{10}\text{B}\) for BPA and \(^{11}\text{B}\) for BSH in future experiments.

**Discussion**

Precise knowledge of the distribution of a drug in tissues with subcellular resolution is not only regarded as crucial...
for the development of drugs for targeted therapies, contrast media, radiopharmaceuticals, and BNCT but also for understanding the mode of action and metabolic characteristics of existing drugs. Our study indicates that laser-SNMS is a sensitive technique for direct imaging of atoms and molecules in tissue with the spatial resolution needed for these purposes. The following points support this conclusion:

An ion beam diameter of 500 nm was sufficient to obtain images with subcellular resolution. An even higher resolution could be achieved by an increase of analysis times.

We were able to correlate the distribution of the atom of interest, in our case, $^{10}$B with distinct histologic structures, especially the cell nucleus, by coregistration of the distribution of index molecules/molecular fragments. This spatial correlation offers tremendous potential for the interpretation of biological processes in general and, in the context of our study, for precise evaluation of the biodistribution of candidate drugs.

Other authors have suggested to combine the histologic interpretation of mirror-stained tissue directly neighboring the analyzed sample with information obtained from analytical techniques (e.g., from high-resolution α-autoradiography in BNCT; refs. 27, 28). These techniques, however, do not allow subcellular spatial resolution. In principle, the approach shown here may also benefit from histologic analysis of mirror-stained slices neighboring the analyzed surface. However, the quality of the stained sections is limited because they have to be fractured off.

**Figure 3.** Row 1, ion-induced electron image of the surface and histologic image of the tumor (H&E staining) composed mainly of spindle cells. Rows 2 and 3, laser-SNMS images of the distribution of Na, K, P, Ca, $^{10}$B, CN, and $C_3H_8N$ in a murine sarcoma tumor (xenografted on a nude mouse) after treatment with BSH (200 mg/kg). Black, lowest signal intensity; white, highest signal intensity. Row 4, overlay of the signals from CN and $C_3H_8N$ (left) and $^{10}$B and $C_3H_8N$ (right).
tissue samples at very low temperatures (143 K; ref. 29) instead of using cutting procedures at higher temperatures (253 K) or resin-embedding procedures. Such conventional fixation and embedding techniques cannot be applied for our purpose because diffusible substances are likely to be redistributed or even lost during sample preparation. Molecular target compounds such as proteins, fatty acids, or drugs might be displaced during fixation.

Laser-SNMS allows for the identification of specific atoms and molecules and the analysis of their distribution in biological samples and therefore has crucial advantageous over other methods such as chemical staining, immunohistochemical tags, and radiolabels, which are common methods for visualizing and identifying molecular targets. Such methods are especially limited with respect to specificity and to the number of target compounds, which can be monitored simultaneously (30). Moreover, use of specific molecular tags requires a priori knowledge of the target species, thereby limiting their usefulness for molecular discovery.

SIMS, an alternative technique for element- and molecule-specific imaging, has also been used for imaging boron compounds in cell cultures (31, 32) and tissues (33, 34). However, its application for imaging drugs is substantially hampered due to its lack of sensitivity and accuracy. Laser-SNMS, with the same technical features as SIMS, decouples the sputtering and ionization processes using laser beams to ionize the majority of neutral particles sputtered from the sample surface. The neutral particles yield is less affected by the chemical composition of the surface than the much smaller yield of secondary ions used for SIMS analysis, resulting in a significantly higher sensitivity and...
accuracy of laser-SNMS than SIMS. Furthermore, laser-SNMS images are significantly less influenced by topographical effects than SIMS images because the sputtered neutrals are not extracted directly from the surface, as SIMS ions are, but from a defined volume above the surface (35).

Quantification of elements with laser-SNMS has already been shown in cell cultures (23) and was not part of this study.

Laser-SNMS can simultaneously detect elements such as cisplatinum, gadolinium, fluoride, and iodine contained in drugs or molecular fragments of drugs.

The especially developed cryopreparation technique preserves the tissue samples in a state that is close to its natural existence and largely avoids structural artifacts caused by tissue extraction thus minimizing redistribution artifacts for diffusible elements (24).

However, due to the sophisticated preparation and time-consuming measurements, laser-SNMS is not suited as a screening technique in drug development. This can be achieved by use of a complementary technique. In the context of BNCT, the combination of PGRA and laser-SNMS proved to be highly effective.

For this investigation, the concept was to efficiently assess the potential of BSH and BPA in sarcoma. PGRA or alternative methods, such as inductively coupled plasma-atomic emission spectroscopy, can effectively measure the $^{10}$B concentration in macroscopic samples to estimate the absolute $^{10}$B concentration. Such data can be used to conclude as to whether the amount of boron in a tumor is sufficiently high for treatment and if $^{10}$B, as delivered by a specific drug, accumulates in healthy organs revealing organs at risk. This screening method (high throughput)

![Image of murine sarcoma](https://example.com/image.png)

**Figure 5.** Images of the murine sarcoma MuEs after treatment with BPA and BSH. Row 1, ion-induced electron image of the sample surface. Rows 2 and 3, laser-SNMS images of the distribution of Na, K, P, Ca, $^{10}$B, CN, and C$_3$H$_8$N in a murine sarcoma tumor (xenografted on a nude mouse) after treatment with and BSH (200 mg/kg) and BPA (700 mg/kg). Black, lowest signal intensity; white, highest signal intensity. Row 4, overlay of the signals from CN and C$_3$H$_8$N (left) and $^{10}$B and C$_3$H$_8$N (right).
can ideally be supplemented for promising compounds by laser-SNMS, which can image the $^{10}$B distribution with subcellular spatial resolution thus allowing to estimate the effect of boron neutron capture reactions during neutron irradiation. The combination of results from both methods moreover allowed conclusions to be drawn, which are not possible with either technique alone.

In this study, BSH and BPA were applied in the MuEs tumor model. PGRA revealed that BPA might be suitable for a BNCT treatment due to the accumulation of $^{10}$B in the tumor compared with blood and all normal tissues investigated. After injection of BSH alone, $^{10}$B was not increased in the tumor compared with blood; however, surprisingly, the $^{10}$B concentration was found to be higher in the tumor as in healthy organs. The $^{10}$B concentration ratio between tumor and muscle was clearly higher as the ratio, which could be achieved with BPA, therefore rendering BSH also an interesting candidate for further testing. Following an observation of Yokoyama et al. (36) and Chandra et al. (32), the sequential injection of BSH and BPA was investigated with the hypothesis that due to the differing uptake mechanisms and pharmacokinetics of these compounds, their combination might enhance the absolute $^{10}$B concentration in the tumor, and even more important, it may increase the $^{10}$B concentration ratios between tumor and healthy tissue. However, our study showed that the sequential injection of both compounds only increased the absolute $^{10}$B concentration in tumor tissue but failed to improve the $^{10}$B ratio of the tumor relative to healthy tissues.

This investigation with laser-SNMS was the first study to compare the biodistribution of $^{10}$B as delivered by BSH and BPA in tissue samples with a subcellular spatial resolution. It could be shown that both compounds are capable of delivering $^{10}$B to the desired target, the cell nucleus, but also to further intracellular compartments. Our study confirmed most assumptions from cell culture experiments by Chandra et al. (32). As opposed to their work, however, within the tumor tissue, we observed a markedly heterogeneous distribution of BPA delivered $^{10}$B on both intracellular and intercellular levels. Several mechanisms (differing blood supply, proliferating and metabolic activity, and expression of L-amino acid transporter at the cell membrane) might be responsible for this observation. A heterogeneous microdistribution of $^{10}$B has already been postulated by Ono et al. (37) from radiobiological experiments.

Unlike the well-known cellular uptake of BPA by the L-amino acid transport system (38, 39), the uptake mechanism of BSH is still not understood. Due to the almost equal $^{10}$B concentrations in tumor tissues and blood, BSH has not been considered as useful to deliver $^{10}$B to peripheral tumors, at least not until the combined injection of BSH and BPA was proposed (37) to supposedly reach a more homogeneous $^{10}$B distribution. Our results proved that injecting both compounds leads to a more homogeneous $^{10}$B distribution in the tumor while maintaining the tumor/blood and tumor/healthy tissue ratios at an acceptable level. The combined application of BSH and BPA thus most likely will contribute to an increased efficacy of a BNCT treatment.

With PGRA, we could not prove a significantly improved ratio between tumor and healthy tissues after injection of BSH and BPA compared with BPA alone. However, the favorable ratios after BSH injection alone in muscle and fatty tissue merits further investigation (to optimize the timing of drug delivery for tumors located at the extremities surrounded by muscles and fat). As the $^{10}$B concentration in blood and the tumor is equally high, blood vessels have to be regarded as organs at risk. On the other hand, as suggested by Trivillin et al. (40), an impaired function of blood vessels may contribute to the effect of BNCT in the tumor.

We conclude that laser-SNMS is a powerful tool for imaging specific element-containing drugs, which may have tremendous effect on both drug discovery and development. In addition to drug development in BNCT, laser-SNMS may be applied for the development of targeted drugs in oncology, contrast agents, and diagnostic and therapeutic radiopharmaceuticals in nuclear medicine, which all demand precise knowledge of their distribution in tissues and cells.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Gero Hilken (Central Animal Facility, University Hospital Essen) and Michael Gronberg (Department of Radiation Oncology, University Hospital Essen) for technical assistance with animal experiments and Klaus Dutschka (Department of Nuclear Medicine, Nuclear Chemistry and Radiopharmaceutics, University Hospital Essen) for help with preparing the compound solutions.

References


Molecular Cancer Therapeutics

Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs

Andrea Wittig, Heinrich F. Arlinghaus, Christian Kriegeskotte, et al.


Updated version  Access the most recent version of this article at: http://mct.aacrjournals.org/content/7/7/1763

Cited articles  This article cites 39 articles, 4 of which you can access for free at: http://mct.aacrjournals.org/content/7/7/1763.full.html#ref-list-1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.